Engrail Therapeutics Inc

This study tested an experimental drug called ENX-102 in 47 adults with social anxiety disorder. Participants received either the drug or a placebo to see if it reduced fear and avoidance in social situations. The goal was to measure safety and how well the drug works as a standa…

This early-stage study tested a new drug called ENX-104 in 48 adults with major depressive disorder who also experience anhedonia (loss of interest or pleasure). The main goal was to check the drug's safety and how the body processes it. The study is now complete, and results wil…

This study tested a new drug called ENX-102 in 252 adults with generalized anxiety disorder. Participants received either the drug or a placebo for several weeks. Researchers measured changes in anxiety symptoms using a standard rating scale. The goal was to see if ENX-102 reduce…

This study tested a new drug called ENX-102 in 38 adults with generalized anxiety disorder. Participants received either a low, mid, or high dose of ENX-102 or a placebo for six weeks. The goal was to check safety and find the best dose. The trial is now complete.

This early-stage study tested a single dose of ENX-205 in 59 healthy adults to see if it is safe and how the body processes it. Researchers also used brain scans to measure how much of the drug reaches its target in the brain. The goal was to gather safety information, not to tre…

This early-stage trial tested a single dose of the experimental drug ENX-104 in 12 healthy volunteers. The goal was to see how the body absorbs the drug when given as a liquid or a tablet, and whether a high-fat meal changes absorption. No treatment for any disease was studied; t…

This completed early-phase study gave a single oral dose of ENX-104 to 10 healthy volunteers to check its safety, how the body processes it, and how well it binds to D2/D3 receptors in the brain. The main goal was to track any side effects. Since this was a small, first-in-human …